Keyphrases
Acquired Resistance
20%
Ann Arbor Staging
23%
Combination Chemotherapy
20%
Conjunctival Lymphoma
20%
Differential Expression
20%
Diffuse Large B-cell Lymphoma (DLBCL)
100%
Disease-specific Survival
41%
Dual Inhibition
20%
Dysplastic Changes
23%
Enhancer of Zeste Homolog 2 (EZH2)
20%
Extranodal Marginal Zone B-cell Lymphoma
20%
Extranodal Marginal Zone Lymphoma
36%
Eyelid
20%
Flow Cytometry
20%
Follicular Lymphoma
76%
Hotspot mutation
20%
Idiopathic Cytopenia of Undetermined Significance
41%
IKZF3
20%
Immunomodulatory Drugs (IMiDs)
41%
International multicenter Study
20%
Intrinsic Resistance
20%
Lacrimal Gland
27%
Lenalidomide
32%
Lymphoma
87%
Lymphoma Patients
31%
Malignant Lymphoma
31%
MALT Lymphoma
20%
Mantle Cell Lymphoma
82%
MicroRNA
20%
MicroRNA-155 (miR-155)
20%
MicroRNA-21 (miR-21)
20%
Multicenter Cohort
20%
Multicenter Retrospective Study
62%
Multiple Myeloma
23%
Myelodysplastic Syndrome
25%
Myeloma Cells
20%
Ocular Adnexal
79%
Ocular Adnexal Region
44%
Overall Survival
26%
Primary Central Nervous System Lymphoma (PCNSL)
20%
Prognostic Role
20%
Progression-free Survival
21%
Radiotherapy
23%
Rituximab
21%
Single-center Analysis
20%
Splicing mutation
20%
Stroma Cells
20%
Tumor Cells
20%
Tumor Protein p53 (TP53)
24%
Tumor Suppressor miRNA
20%
Medicine and Dentistry
Adnexa
20%
B Cell
28%
Clinical Feature
28%
Cytopenia
20%
Diagnosis
20%
Diffuse Large B-Cell Lymphoma
93%
Disease Specific Survival
55%
Diseases
28%
External Beam Radiotherapy
38%
Flow Cytometry
20%
Follicular Lymphoma
97%
Lacrimal Gland
36%
Lymphoma
20%
MALT Lymphoma
60%
Mantle Cell Lymphoma
82%
Mycosis fungoides
18%
Overall Survival
53%
Progression Free Survival
20%
Retrospective Study
62%
Rituximab
27%
Survival Rate
18%
